Aspira Pathlab board meets Sept 12 to consider fund raising

0 min read | Published on 07 Sept 2026, 03:10 PM |Updated on 07 Sept 2026, 03:10 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Key Highlights

Aspira Pathlab & Diagnostics Ltd holds board meeting on September 12, 2026
Agenda includes proposal to raise funds via equity shares or convertible warrants
Methods may include preferential issues, private placements, or rights issues
Action taken under SEBI Listing Regulations and ICDR Regulations

*this image is generated using AI for illustrative purposes only.

Aspira Pathlab & Diagnostics Limited has scheduled a meeting of its Board of Directors for September 12, 2026. The agenda includes considering proposals for raising funds through the issuance of equity shares or warrants convertible into equity.

The company intends to evaluate methods such as preferential issues, private placements, or rights issues. This move comes under the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Regulatory Compliance

The intimation was issued pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice confirms that the Board will also transact other incidental and ancillary matters as decided during the session.

Next Steps

The formal notice for the Board Meeting will be uploaded on the company’s website in compliance with Regulation 46(2)(l)(i) of the Listing Regulations. Shareholders and stakeholders are advised to monitor official disclosures for further updates on the capital raising process.

Historical Stock Returns for Aspira Pathlab

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
0.0%	+6.01%	-14.54%	+70.18%	+51.56%	0.0%

What specific strategic initiatives or expansion plans is Aspira Pathlab funding with this equity raise?

How might the chosen method of capital raising (preferential, private placement, or rights issue) impact existing shareholder dilution?

Will the current market valuation of Aspira Pathlab support a premium pricing for the new equity shares or warrants?

Aspira Pathlab

View Company Insights

View All News

Aspira Pathlab promoter Jay Arvind Bhanushali acquires 957 shares

0 min read | Published on 03 Sept 2026, 10:30 AM |Updated on 03 Sept 2026, 10:30 AM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

Key Highlights

Promoter Jay Arvind Bhanushali bought 957 shares via open market
Stake increased from 7.24% to 7.25% in the diagnostics firm
Total holding stands at 7,45,754 equity shares post-acquisition
Disclosure filed under SEBI SAST Regulation 29(2)

*this image is generated using AI for illustrative purposes only.

Promoter Jay Arvind Bhanushali acquired 957 equity shares of Aspira Pathlab on August 31, 2026, through open market transactions. The purchase represents a 0.01% increase in his voting stake.

The acquisition was disclosed to the BSE Limited under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Bhanushali’s total holding rose from 7,44,797 shares (7.24%) to 7,45,754 shares (7.25%).

What the Numbers Show

The transaction involved only equity shares carrying voting rights. There were no changes in encumbered shares, warrants, or convertible securities. The company’s total equity share capital remained unchanged at ₹10,29,30,000, divided into 1,02,93,000 equity shares of ₹10 each.

Historical Stock Returns for Aspira Pathlab